Neuro-Innovators, LLC
Clinical-stage pharmaceutical company developing combination drug therapies engineered to enhance neuroplasticity for functional brain restoration. Focused initial development on oral multi-drug formulations to improve motor recovery in chronic stroke survivors through investigator-led clinical studies and a regulatory strategy relying on repurposed, FDA-approved compounds.
Industries
N/A
Products
Oral three-drug combination therapy (lead clinical candidate)
A once-daily oral combination of three FDA-approved, brain-penetrant compounds engineered to enhance neuroplasticity when administered alongside intensive rehabilitation to improve motor recovery in chronic stroke survivors.
Oral three-drug combination therapy (lead clinical candidate)
A once-daily oral combination of three FDA-approved, brain-penetrant compounds engineered to enhance neuroplasticity when administered alongside intensive rehabilitation to improve motor recovery in chronic stroke survivors.
Services
Clinical trial collaboration and investigator-initiated study support
Partnerships with rehabilitation hospitals and investigator teams to run proof-of-concept clinical studies integrating pharmacologic interventions with standard rehabilitation protocols.
Clinical trial collaboration and investigator-initiated study support
Partnerships with rehabilitation hospitals and investigator teams to run proof-of-concept clinical studies integrating pharmacologic interventions with standard rehabilitation protocols.
Expertise Areas
- Clinical trial management (investigator-initiated studies)
- Neuropharmacology and polypharmacy design
- Regulatory strategy (505(b)(2) / FDA fast-track)
- Biomarker development and longitudinal clinical analytics
Key Technologies
- Combination/polypharmacy therapy design
- In-silico compound screening
- Blood-based biomarker assays
- Robot-assisted neurorehabilitation